Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.
Nat Commun. 2021 Jan 13;12(1):352. doi: 10.1038/s41467-020-20469-6.
Nat Commun. 2021.
PMID: 33441554
Free PMC article.